TickerGraveyard
TickerGraveyard

VCBX

Delisted
VectivBio Holding AG

VCBX — Post-Mortem

VectivBio Holding AG, founded to advance innovative therapies in the life sciences sector, filed for voluntary delisting from the Nasdaq on July 10, 2023. The company's peak came in a competitive biotech landscape, driven by hopes of developing impactful treatments. However, regulatory compliance and possibly strategic recalibrations prompted their decision to withdraw from listing, marking the end of their public trading era and reflecting broader challenges in the biotechnology space.

VectivBio Holding AG was delisted from the Nasdaq following a voluntary withdrawal of its ordinary shares effective July 10, 2023.

Could I Have Seen This Coming?

No structured pre-delisting signals found in our records. Absence of signals does not imply absence of risk.

Post-Mortem Analysis

Five-section narrative grounded in primary filings and contemporaneous reporting.

Origin

VectivBio was established as a biotechnology firm focused on transforming science into novel therapies, utilizing cutting-edge research to address unmet medical needs.

Peak

The company operated in the biotech space with significant investor interest due to its innovative pipeline, marking a peak in market visibility and valuation.

Turning Point

The decision to withdraw was a critical turning point, likely reflecting internal assessments of strategic alignment and market conditions.

End

The company was delisted on July 10, 2023, after filing a Form 25 for voluntary withdrawal.

Impact

The delisting effectively terminated VectivBio's access to public capital markets and removed its ordinary shares from Nasdaq, impacting shareholder liquidity.

Lessons for Today's Investors

Transferable patterns identified from this case, written as research-report observations.

  1. 1

    Companies should ensure sustainable compliance with exchange rules to avoid delisting.

  2. 2

    Voluntary delisting can signal underlying operational or strategic challenges that might concern investors.

  3. 3

    Maintaining open communication with investors during significant corporate changes is essential to preserve trust and investor confidence.

Frequently Asked Questions

Why was VectivBio Holding AG delisted from the Nasdaq?
VectivBio Holding AG was delisted from the Nasdaq following a voluntary withdrawal of its ordinary shares from listing and registration under the Securities Exchange Act of 1934.
When did VectivBio Holding AG file the Form 25 for delisting?
VectivBio Holding AG filed the Form 25 for delisting on July 10, 2023.
What were the main legal provisions cited for the delisting?
The delisting was executed under 17 CFR 240.12d2-2(c), which governs the voluntary withdrawal of class securities from listing and registration.
Who was the authorized representative for VectivBio in the delisting process?
Sravan K. Emany signed the Form 25 as the authorized representative of VectivBio.
What is the nominal value of VectivBio's ordinary shares?
The nominal value of VectivBio's ordinary shares is CHF 0.05 per share.

Source Filings

Every fact on this page is anchored to a primary SEC filing or regulatory record. Open any source to verify against the original document.

Narrative sections on this page are AI-assisted summaries of the filings linked above. All content is reviewed against primary sources; if you find an error, the canonical record is always the linked filing.

Industries:

Tags:

Related tickers:

Share: